Metformin in Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 440 participants.

Also called NCT07899307

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 440 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07899307
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
India (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07899307. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2030-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin in Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
Placebo
Intervention (Drug)
Metfomin
Lead sponsor
All India Institute of Medical Sciences (class: other)
Collaborator
Jawaharlal Institute of Postgraduate Medical Education & Research (class: other government)
Collaborator
Postgraduate Institute of Medical Education and Research in Chandigarh (class: other)
Collaborator
Institute of Medical Sciences of the Banaras Hindu University, India (class: other)
Collaborator
Indian Council of Medical Research (class: other government)

Record details

Record id
cardio:ct-nct07899307
Content hash
928c95ff2eaa4405e5c41a231fd720c8bc323ad308fbb97b8dcdef0f2111a2c6